Enter multiple symbols separated by commas

Commentary: Listen, Feds: Leave UBS Alone!

The US government is going after Swiss banks to hand over their super-secret account details. This is so wrong.
Leave UBS alone. It is hypocritical on the part of our government to do this.

Do you know which country is the biggest tax haven in the entire world? The United States!

Foreigners have more than $4 trillion dollars in passive investments in the form of bank accounts or brokerage accounts in the US, according to Treasury figures that Dan Mitchell from the CATO Institute helped me dig up.

And guess what. The US does not tax interest or passive capital gains on foreigners. Yup, you read that right: The US government gives HUGE tax breaks to foreigners. Why? Because we want their money and we want to attract their capital to our economy.

If a foreign government came to the United States and said "hand over information about all our citizens," we would tell them to go blow smoke. We don't do that. But now Congress wants Switzerland to do the same with UBS . It's wrong.

Tax competition is a good thing. It should happen between states; it should happen between countries. The countries in the world that have the highest rates of tax evasion are the countries with the highest tax rates. That should be a lesson to governments, not a reason to prosecute.

More from Michelle Caruso-Cabrera:

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • WiFi via drones

    Facebook wants to keep growing and has designed a drone that will provide Internet service in remote areas. CNBC's Julia Boorstin reports.

  • SoulCycle files for IPO

    CNBC's Dominic Chu reports the banks listed for underwriters for the SoulCycle IPO.

  • Street Talk: ORCL, SCTY, WDC, SFLY & RLYP

    "Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including biotech Relypsa.